Investigational drug · Phase 2
VMD-3866
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "VMD-3866"
First trial start
2025
Dec 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VMD-3866", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chemotherapy-induced Peripheral Neuropathy
- Chemotherapy-induced Neuropathic Pain
- CIPN - Chemotherapy-Induced Peripheral Neuropathy
- Peripheral Neuropathic Pain
- Peripheral Nerve Injuries
- Pain, Nerve
- Pain, Chronic
- Pain, Neuropathic
- Peripheral Nerve Injury Lower Leg
- Peripheral Nerve Injury at Ankle and Foot Level (Diagnosis)
Approved drugs for the same conditions: Neuropathic pain · Neurology · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "VMD-3866" as an intervention, largest first.
VM Therapeutics LLCIndustry
NCT07072468 · 16 participants (planned) · Start Dec 12, 2025 · Primary completion Jun 30, 2027
Drug: VMD-3866 Gel; Placebo Gel · For: Chemotherapy-induced Peripheral Neuropathy; Chemotherapy-induced Neuropathic Pain; CIPN - Chemotherapy-Induced Peripheral Neuropathy and 14 more
Sites: London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chemotherapy-induced Peripheral Neuropathy
- SIR2501Phase 21 trial
Sironax USA, Inc. · Chemotherapy-induced Peripheral Neuropathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.